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Background: The outcomes of patients with diabetes mellitus (DM) who are referred to surgical aortic valve
replacement are poor in comparison to non-diabetic (ND) patients. However, the outcome of diabetic patients
referred to transcatheter aortic valve replacement (TAVR) is less established. Further, DM and AS are both asso-
ciated with left ventricular hypertrophy. It is not clear if alleviation of AS results in greater degree of reverse
remodeling in DM patients in comparison to ND. We aim to evaluate if diabetes mellitus has an impact on
TAVR outcome and remodeling patterns.
Methods: All consecutive patients who underwent TAVR (2007–2012) were included in this analysis. A compar-
ison of baseline, procedural, post-procedural outcomes and echocardiographic left-ventricle mass indices was
performed between DM and ND patients.
Results: DM was prevalent in 165 of 499 (33.0%) consecutive patients who underwent TAVR. DM patients
were younger, weighed more, had higher rates of renal insufﬁciency and larger caliber peripheral vessels.
Other than that, no disparities were noted in baseline characteristics. Procedural aspects were mostly
similar between the groups but ND patients had higher rates of both vascular complications and bleeding.
This did not translate into statistically signiﬁcant differences in mortality both at 30 days and at 1 year (DM
6.7% vs. ND 10.5%; p= 0.16 and DM 22.4% vs. 25.7%; p= 0.48, respectively). Incidences of reverse remod-
eling patterns were similar between the two groups.
Conclusion: TAVR outcome is probably driven by baseline characteristics and post-operative complications
while diabetes itself is not associated with poor outcome after TAVR.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Patientswith diabetesmellitus (DM) are at increased risk for athero-
sclerosis and their outcome is poor compared to non-diabetic (ND)
patients when diagnosed with cardiovascular disease [1,2]. Within this
population, patients treated with insulin and those with poor glycemic
control were reported to have poorer outcomes compared to those
treatedwith other hypoglycemic strategies and adequate glycemic con-
trol [3–6]. Aortic stenosis (AS) is one of the most prevalent valvular
diseases. By its virtue, AS initiates a cascade of intra- and extracellular
events resulting in ventricular hypertrophy,which in turn, ismanifested
as diastolic dysfunction. Recent reports indicate that this process is
exaggerated in DM patients with concomitant AS [7]. Furthermore,
diabetes was associatedwith increased risk for aortic valve calciﬁcation,al Center, 110 Irving Street, NW,
an).
land Ltd. This is an open access articlwhich is the initial pathological process that leads to aortic stenosis [8].
Prior studies have indicated that DM is associatedwith an increased risk
for mortality in patients undergoing surgical aortic valve replacement,
with a higher probability formortality in DMpatients treatedwith insu-
lin [9–11]. Transcatheter aortic valve replacement (TAVR) has become
an alternative for conventional aortic valve replacement in speciﬁc pa-
tient subsets. Data from the Placement of Aortic Transcatheter Valves
(PARTNER) Trial demonstrated a survival beneﬁt for diabetic patients
undergoing TAVR versus those who underwent surgical valve replace-
ment. No evidence, however, for a similar beneﬁt was demonstrated
in the pivotal CoreValve trial [12,13]. Thus, the merits of DM in patients
undergoing TAVR are less clear.
Further, both AS and DM are associated with left-ventricular (LV)
hypertrophy and increased LV mass [14,15]. TAVR was previously
associated with “reversed remodeling” after relieving the increased
afterload off the LV wall [16] but it is unknown whether patients
with concomitant AS and DM have higher degrees of reverse remod-
eling in comparison to patients with no DM.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and outcomes of DM to ND patients undergoing TAVR, and to further
evaluate the impact of glycemic control and glucose lowering thera-
py on such outcomes. We further aimed to explore differences in
echocardiographic hypertrophy and LV mass regression patterns
hypothesizing that AS patient with concomitant DM will have a
lower degree of LV mass regression in comparison to ND patients.
2. Methods
Consecutive patients with severe, symptomatic AS treated with
TAVR were included. The study was approved by the local institutional
review board at the MedStar Washington Hospital Center. After metic-
ulous screening, TAVR eligibility was determined by a Heart Team that
includes both interventional cardiologists and cardiac surgeons. Screen-
ing for eligibility included a detailed past medical history and physical
examination, frailty tests, echocardiography with Doppler measure-
ments, computerized tomography with contrast to evaluate the poten-
tial access sites, and coronary angiography. A patient's surgical risk was
determined by the surgeons alongside calculation of the Society of
Thoracic Surgeons (STS) score. The criteria for eligibility followed the
deﬁnitions of the PARTNER [17,18] and CoreValve [13,19] clinical trials
and the indication for commercial use of the Edwards SAPIEN valve
(Edwards Lifesciences, Irvine, CA) after approval by the Food and Drug
Administration [20–22]. The technical aspects of TAVR in our center
were previously described [23]. The decision to use a self-expandable
or balloon-expandable valve was dependent on the availability of the
device (self-expandable valves were available only a few years after
balloon-expandable), access suitability (i.e., transapical access wasTable 1
Baseline characteristics.
Di
(n
Variables
Age (years ± SD) 81
Male gender 88
Society of Thoracic Surgeon risk score (mean ± SD) 9.
Weight (kg ± SD) 84
Body surface area (m2 ± SD) 1.
Hypertension 15
Hyperlipidemia 14
Chronic obstructive pulmonary disease 54
Peripheral vascular disease 57
Cerebrovascular event/transient ischemic attack 25
Atrial ﬁbrillation/ﬂutter 61
Renal insufﬁciency (GFR b 60 cm3/min/1.73 m2) 99
Severe renal insufﬁciency (GFR b 3060 cm3/min/1.73 m2) 14
Dialysis dependency 4/
Prior balloon aortic valvuloplasty 55
Pre-procedural coronary artery disease 11
New-York Heart Association Classes III–IV 14
Minimal Lumen Diameter of ilio-femoral vessels (right; mm ± SD) 7.
Minimal Lumen Diameter of ilio-femoral vessels (right; mm ± SD) 7.
Pre-procedural echocardiographic parameters
Ejection fraction (% ± SD) 51
Mean aortic valve gradient (mm Hg ± SD) 45
Maximal aortic valve velocity (m/s ± SD) 4.
Moderate aortic regurgitation 3/
Moderate/moderate–severe aortic regurgitation 0
Moderate mitral regurgitation 10
Moderate–severe mitral regurgitation 1/
Severe mitral regurgitation 1/
Valve program disposition
Clinical trial (CoreValve/PARTNER) 11
Commercial transcatheter aortic valve replacementa 4
Inoperable patientsb 5
GFR = glomerular ﬁltration rate.
a Refers to procedures performed after FDA's approval.
b Inoperable status was determined by a cardiac surgeon and followed the PARTNER and Coavailable only for the balloon expandable valve) and other technical
matters (e.g., self-expandable valves were preferred in patients with
severe calciﬁcation at the left ventricle outﬂow tract).
Clinical, procedural, and laboratory data were collected for all
patients during screening, on admission, immediately post-procedure,
and during follow-up. This included demographic information, past
medical history (as detailed by the referring physician or hospital
records), clinical data (e.g. echocardiographic indices and baseline elec-
trocardiogram) and laboratory indices including glycosylated hemoglo-
bin (HbA1c). Referring physician notes and prior hospitalization were
used as source documentation for the patient's prior medical history
(including systemic hypertension and DM) and medical therapy. Col-
lected procedural data included, among others, the amount of contrast
injected, procedure length, devices used for valve implantation (includ-
ing valve type, size, delivery system, andmeans of vascular access), and
immediate complications. Post-procedural data used hospital docu-
ments as a primary source for laboratory results, length of stay, and
in-hospital complications. Follow-up data was collected during sched-
uled clinical trials visits and from scheduled phone calls or clinic visits
for the rest of the patients. Clinical events were adjudicated by an inde-
pendent cardiologist who determined the nature of the event.
For the evaluation of LV geometry patterns and the assessment of
the regression of hypertrophy post-TAVR, the following echocardio-
graphic indices followed the American Society of Echocardiography
deﬁnitions [24]:
• LV mass (LVM) = 0.8 ∗ (1.04 [(LV end diastolic diameter + posterior
wall thickness in diastole + septal well thickness in diastole)3− (LV
end diastolic diameter)3]) + 0.6.abetes mellitus
= 165)
No diabetes mellitus
(n= 334)
p value
.40 ± 8.09 84.46 ± 7.30 b0.001
/165 (53.3%) 159/334 (47.6%) 0.272
85 ± 4.65 9.66 ± 4.51 0.677
.88 ± 21.73 71.50 ± 19.74 b0.001
92 ± 0.25 1.77 ± 0.24 b0.001
7/165 (95.2%) 308/334 (92.2%) 0.221
2/163 (87.1%) 247/333 (74.2%) b0.001
/165 (32.7%) 106/332 (31.9%) 0.857
/159 (35.8%) 117/328 (35.7%) 0.969
/158 (15.8%) 55/319 (17.2%) 0.696
/165 (37.0%) 149/334 (44.6%) 0.104
/161 (61.5%) 161/331 (48.6%) 0.007
/136 (10.3%) 17/258 (6.6%) 0.194
161 (2.5%) 7/331 (2.1%) 0.755
/148 (37.2%) 96/278 (24.5%) 0.589
3/139 (81.3%) 184/254 (72.4%) 0.051
8/159 (93.1%) 305/328 (93.0%) 0.970
57 ± 0.96 7.22 ± 1.25 0.002
45 ± 1.03 7.23 ± 1.15 0.055
.48 ± 13.95 53.51 ± 13.59 0.126
.52 ± 11.18 48.99 ± 13.22 0.003
28 ± 0.52 4.42 ± 0.55 0.009
122 (2.5%) 13/274 (4.7%) 0.410
0
/140 (7.1%) 31/300 (10.3%) 0.284
140 (0.7%) 4/300 (1.3%) 0.064
140 (0.7%) 1/300 (0.3%) 0.536
8/163 (72.4%) 249/334 (74.65) 0.607
7/163 (28.8%) 97/334 (29.0%) 0.962
9/117 (50.4%) 120/247 (48.6%) 0.742
reValve deﬁnitions.
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surface area (calculated by the Du Bois formula [25]). High relative
wall thickness was deﬁned as index N 95 g/m2 (♀) and N115 g/m2
• (♂).
• Relativewall thickness= (2× posterior wall thickness in diastole / LV
internal dimension at end diastole). Relativewall thickness N0.42was
considered high.
Four patterns of LV geometry were identiﬁed according to the
European Society of Cardiology's recommendation for chamber quanti-
ﬁcation [24]: 1) Normal geometry: normal LV mass index and normal
relative wall thickness; 2) concentric hypertrophy, high LV mass index
and high relative wall thickness; 3) eccentric hypertrophy, high LV
mass index and normal relative wall thickness; and 4) concentric
remodeling, normal LV mass index and high relative wall thickness.
After sorting each patient to a speciﬁc pattern, we evaluated the transi-
tion of each patient from the baseline pattern to the pattern at 30 days
and recorded the rates of transition.
End point deﬁnitions followed the second Valve Academic Research
Consortium deﬁnitions and included: in-hospital mortality, cardiac
death, major vascular complications, stroke, transient ischemic attack,
periprocedural myocardial infarction, post-procedural atrial ﬁbrillation,
and post-procedural permanent pacemaker implantation.
A comparison of the baseline characteristics, procedural data, and
both short and long term outcomes was performed between the pre-
speciﬁed groups (DM versus ND patients). This was followed by a com-
parison of the patterns of regression of the LV mass index. A subgroup
analysis comparison was made between DM subgroups: diabetic pa-
tients treated with insulin therapy versus those on oral hypoglycemic
drugs or diet and between patients with adequate glycemic control
(pre-procedural HbA1c ≤ 6.5%) and those with inadequate glycemic
control (HbA1c N 6.5%).
Statistical analysis was performed by using SAS version 9.2 (SAS Insti-
tute Inc., Cary, NC). Continuous variables are expressed as mean ± stan-
dard deviation for normally distributed variables or median [25%–75%
interquartile range] for non-normally distributed variables. Categorical
variables are expressed as percentages. Student's t test or the Wilcoxon
test was used to compare continuous variables and the χ2 test or FisherTable 2
Procedural characteristics.
Variable Diabetes mellit
(n= 165)
Valve sizea
23-mm 81/171 (47.6%)
26-mm 62/170 (36.5%)
29-mm 19/170 (11.2%)
31-mm 8/170 (4.7%)
Access
Transfemoral 131/165 (79.4%
Transapical 31/165 (18.8%)
Retroperitoneal 3/165 (1.8%)
Direct aortic 0
Resources
Conscious sedation 113/165 (68.5%
Contrast media volume used (median ml. [IQR]) 120.0 [80.0–16
Fluoroscopy Time (median min.[IQR]) 19.3 [14.0–24.6
Procedure Length (median min. [IQR]) 95.0 [64.0–133
Intra-procedural complicationsa
Valve migration 3/171 (1.8%)
Inability to gain access 4/165 (2.4%)
Cardiopulmonary resuscitation/cardioversion 11/165 (6.7%)
Tamponade 0
Complete atrio-ventricular block 13/165 (7.9%)
Post-dilatation after valve deployment 13/165 (7.9%)
a The denominator in some of the variables is larger than the number of patients due to casexact test was used to compare categorical variables. Survival rates up
to 1 year were computed using the Kaplan–Meier estimate, and differ-
ences in parameters were assessed using the log-rank test. For exploring
the question if DM is independently associated with 1 year morality a
multivariate Cox regression analysis was completed with the following
variables forced into the model: DM, STS score, renal insufﬁciency
(deﬁned as glomerular ﬁltration rate b 60mL/min/1.73 m2 or on chronic
dialysis), history of coronary artery disease, chronic obstructive pulmo-
nary disease, major vascular complication (according to the second
ValveAcademicResearchConsortium—VARC2), VARC2major life threat-
ening bleeding and hypertension. All the variables that were forced into
the model had a signiﬁcant hazard ratio in the univariate analysis
(deﬁned as p b 0.2) and were further selected according to their clinical
signiﬁcance. All probabilities are two sided and statistically signiﬁcant
differences were deﬁned as p b 0.05.3. Results
From May 2007 to April 2013, 499 consecutive patients underwent
TAVR and were included in the present study. The mean age of this
cohort was 83.4 ± 7.7 years; those of male gender comprised 49.5%
of the cohort. Of these patients, 165 patients (33.0%) had DM, 465
(93.2%) were hypertensive, 80 (16.8%) had prior cerebrovascular
events/transient ischemic event, and 260 (52.8%) had renal insufﬁcien-
cy. The mean STS score was 9.72 ± 4.55 and the mean LV ejection frac-
tion was 52.8 ± 13.7%.
When the 165 DM patients (33%) were compared to ND patients
(n = 334), several baseline characteristics differed between the two
groups: In comparison to the ND, DM patients were younger, weighed
more, had larger caliber peripheral arteries and had higher rates of
renal insufﬁciency and hyperlipidemia (Table 1). Although the mean
LV ejection fraction was similar, the mean pre-TAVR aortic gradient
was lower in DM compared with that of the ND patients. As detailed
in Table 2, no differences were noted in the utilization of the 2 most
frequently used valve sizes (23 mm and 26 mm), but a higher, non-
statistically signiﬁcant rate of use for both 29-mm and 31-mm valves
was noted in DM patients. All the other intraprocedural were similar
between the two groups.us No diabetes mellitus
(n= 334)
p value
172/330 (52.1%) 0.343
130/330 (39.4%) 0.524
22/330 (6.7%) 0.082
6/330 (1.8%) 0.085
) 242/333 (72.7%) 0.103
80/333 (24.0%) 0.186
7/333 (2.1%) 1.0
4 (1.2%) 0.307
) 211/33 (63.4%) 0.259
0.0] 100 [75–150] 0.06
] 18.3 [12.7–23.7] 0.299
.0] 106.0 [70.0–131.5] 0.911
2/330 (0.6%) 0.344
11/331 (3.3%) 0.782
21/331 (6.3%) 0.891
5/331 (1.5%) 0.175
19/331 (5.7%) 0.361
21/332 (6.3%) 0.518
es in which more than one valve was opened/deployed.
Fig. 1.Kaplan–Meier survival estimate at 1 year for diabetic andnon-diabetic patientswho
underwent transcatheter aortic valve replacement.
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life-threatening bleeding which translated into longer hospitalization
(Table 3). The disparities in baseline characteristics and procedural,
and post-procedural complications did not translate into disparities in
both short- (in-hospital and 30-day) and 1 year mortality between
DM and ND patients (Table 3, Fig. 1). As expected, in a Cox regression
analysis, DM was not independently associated with 1 year mortality
(HR 0.91; 95% CI 0.56–1.47, p= 0.7).
Diabetes therapy data was available for 154 of the diabetic patients
and a subgroup analysis compared DM patients chronically treated
with insulin (n= 50) with those treated with either diet or oral hypo-
glycemic drugs (n = 104). Baseline characteristics were similar be-
tween the 2 groups save for the younger age in the patients treated
with insulin (78.26± 8.06 vs. 82.73± 7.82 years; p=0.001). Both pro-
cedural aspects and post-procedural complication rate were similar
except for the higher rate of use of the 23 mm valves in insulin treated
patients (60.4% vs. 42.5%;p=0.003). Although numerically lower rates
of mortality were recorded at 30 days in patients on insulin therapy,
these differences did not reach statistical signiﬁcance and should be
interpreted cautiously due to the small sample size (4.0% vs. 8.78%;
p= 0.50 and 30.0% vs. 21.2%; p= 0.23, respectively) (Fig. 2).
Pre-procedural HbA1c values were available for 105 of the dia-
betic patients and we thus compared the characteristics and out-
comes of patients with baseline HbA1c ≤ 6.5% (n = 67) to those
with HbA1c N 6.5% (n=38). Aside from the younger age in patients
with HbA1c N 6.5% (79.95± 8.56 vs. 83.54 ± 6.17 years; p=0.005),
a higher rate of severe tortuosity in the iliofemoral vessels (20.0%
vs. 10.7%; p = 0.013) and lower body surface area (1.89 ± 0.22
vs. 2.0 ± 0.24; p = 0.02) all other baseline characteristics, proce-
dural aspects, and post-procedural complication rates were simi-
lar. Numerically a higher mortality rate was recorded in patients
with HbA1c ≤ 6.5% at 30 days but this was not statistically signiﬁ-
cant (7.5% vs. 2.6%; p = 0.4). No differences were further noted inTable 3
Outcome parameter comparison.
Variable Diabetes
mellitus
(n= 165)
No diabetes
mellitus
(n= 334)
p value
Post-procedural length of stay
(median days [IQR])
5.0 [3.0–7.0] 6.0 [4.0–9.0] 0.03
Major vascular complication 9/161 (5.6%) 42/324 (13.0%) 0.013
Need for access site surgical
intervention
6/157 (3.8%) 24/313 (7.7%) 0.108
Need for access site percutaneous
intervention
11/157 (7.0%) 25/313 (9.3%) 0.408
Life threatening bleeding 6/165 (3.6%) 36/330 (10.9%) 0.006
No. of post-procedure blood
transfusion
2 [1–2] 2 [1–4] 0.155
Acute myocardial infarction 0 1/324 (0.3%) 1.0
Acute kidney injury
Stage 1 14/148 (9.5%) 21/281 (7.5%) 0.475
Stage 2 1/148 (0.7%) 3/281 (1.1%) 1.0
Stage 3 1/148 (0.7%) 8/281 (2.8%) 0.173
Stroke (ischemic & hemorrhagic) 7/165 (4.2%) 18/331 (5.4%) 0.566
Need for intubation
post-transcatheter aortic valve
replacement
22/165 (13.3%) 68/332 (20.5%) 0.051
New atrial ﬁbrillation 20/165 (12.1%) 53/328 (16.2%) 0.234
Need for pacemaker implantation 15/165 (9.1%) 20/328 (6.1%) 0.222
Echocardiography
Mild aortic regurgitation 91/151 (60.3%) 190/290
(65.5%)
0.276
Mild–moderate aortic regurgitation 15/151 (9.9%) 31/290 (10.7%) 0.805
Moderate aortic regurgitation 5/151 (3.3%) 12/290 (4.1%) 0.669
Moderate–severe/severe aortic
regurgitation
0 0
Mortality
In-hospital death 8/165 (4.8%) 31/333 (9.3%) 0.081
30-day mortality 11/165 (6.3%) 35/334 (10.5%) 0.166
1-year mortality 37/165 (22.4%) 86/334 (25.7%) 0.4181 year morality rate between the patients with HbA1c N 6.5% and
those with HbA1c ≤ 6.5% (18.4% vs. 19.4%; p = 0.90; Fig. 3).
Complete LV geometric data with 1 year follow-up was available for
176 patients (DM n= 53, ND n= 123). Higher LV mass was recorded
in DM at baseline (230.85 ± 67.26 g vs. 208.87 ± 63.90 g; p b 0.001)
but after adjusting for body surface area these differenceswere not signif-
icant (LVMiDM119.50±29.94 g/m2vs.ND117±32.35 g/m2; p=0.55).
At one year of follow-up no difference was noted in the LVMi (DM
111.14± 28.21 g/m2 vs. 108.51 ± 31.96; p=0.59). The mass regression
observed at 1 year did not differ between the two groups (DM−9.83 ±
28.63 g/m2 vs. ND−6.88 ± 29.75 g/m2; p= 0.54).
When the geometric patterns of hypertrophy were scrutinized, no
differences were noted both at baseline and at 1 year between DM
and ND in the incidence of each of the 4 patterns (p N 0.05 for all,Fig. 4)
with the majority of patients in both groups having a concentric hyper-
trophic pattern at baseline (DM 67.9% vs. ND 58.5%; p = 0.24). Fig. 5
depicts the rates of transition from one geometric pattern to the other
from baseline to 1 year follow-up. It is evident that the most frequent
transition of patients between geometric patterns was the regression
in mass demonstrated as the transition between concentric hypertro-
phy at baseline and concentric remodeling at 1 year for both DM and
ND patients. No statistically signiﬁcant differences were noted between
DM and ND patients in the rate of transition to other patterns.Fig. 2. Kaplan–Meier survival estimate at 1 year for non-diabetic and diabetic patients
treated with either insulin or oral hypoglycemic drugs/diet.
Fig. 3. Kaplan–Meier survival estimate at 1 year for diabetic patients who underwent
transcatheter aortic valve replacement with baseline HbA1c ≤ 6.5% versus those with
HbA1c N 6.5%.
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The main results of this study indicate that: 1) Both short- and long-
term outcomes of DM patients undergoing TAVR are mostly similar to
ND patients; 2) no differences in outcome were noted among DM
patients in different glycemic control groups or among patients with
different diabetic therapy regimens; and 3) no differences were record-
ed in the rates and patterns of LV mass regression.
DM impacts greatly on mortality and morbidity in the general pop-
ulation and more importantly, in the context of cardiovascular disease
[2,26,27]. It is considered a risk factor for poor outcome in the Society
of Thoracic Surgeons score model and in recent meta-analysis demon-
strated that DM patients had an 83% increased risk for mortality at
1 year compared to ND patients after coronary artery bypass surgery
[28]. In patients referred to surgical aortic valve replacement, DM was
reported as an independent predictor for 1-year mortality [9,11].
TAVR is considered a less invasive alternative for surgical aortic valve
replacement and thus may be a beneﬁcial alternative for diabetic
patients. Similar to prior TAVR studies [12,29,30], 1/3 of the patients in
the present studywere diabetic,which signiﬁes the interest of exploring
the outcomes of this high risk subset of patients. Conﬂicting evidenceFig. 4. Rates of left ventricular geometry patterns of diabetic and non-diabetic patients who u
intergroup comparison).exists regarding the outcome of DM patients referred to TAVR: Poorer
outcomes were reported in DM patients compared with ND patients
in the Ibero-American registry [31]. DMwas also reported as a predictor
for bleeding and renal failure in TAVR [32,33]. Tamburino et al. reported
that DM was an independent predictor for 30-day mortality (hazard
ratio 2.45 [1.19–5.07]; p = 0.02) but not at 1 year in their cohort of
663 patients [30]. On the other hand, in a more recent study with a co-
hort of 511 patients who underwent TAVR, no differences in outcome
were noted between the DM and ND patients, but poorer outcome
was recorded in the subgroup of insulin-dependent diabetics [29].
When high-risk diabetic patients were eligible for surgery and were
randomized to either TAVR or surgical aortic valve replacement in the
PARTNER high-risk cohort, 9% absolute risk reduction in 1-year mortal-
ity risk was noted in DM patients randomized to TAVR compared to
those who underwent surgical replacement of the aortic valve [12].
Opposite to that, no differences were reported in the outcome of pa-
tients undergoing TAVR in the pivotal CoreValve trial compared with
those who underwent surgical valve replacement [13]. The present
data adds to the accumulating data demonstrating no disparities in
both short- and long-term outcomes between DM and ND patients
referred to TAVR as opposed to those demonstrated in aortic valve
surgery. It hypothesized that this lack of disparity in the outcome of
DMpatients undergoing TAVR stems from the fact that patients referred
to TAVR usually have other signiﬁcant co-morbidities that collectively
drive the outcome and thus DM as a single co-morbidity does not
have a signiﬁcant impact to offset the outcome.
DM is heterogeneous disease with signiﬁcant variability in the
glucose control strategies and the actual achieved glycemic control.
Patients treated with insulin have poorer outcomes compared to pa-
tients treated with oral hypoglycemic or diet in the setting of acute
myocardial infarction [4], after deployment of drug-eluting stents
[3] and after coronary artery bypass grafting surgery [34]. It is still
debatable whether the insulin directly affects outcome or if it is a
meremarker of advanced diabetes. As opposed to the current results,
demonstrating similar outcomes for patients on insulin therapy ver-
sus those on diet/oral hypoglycemic drugs, results from a previous
study including 72 patients treated with insulin who underwent
TAVR demonstrated inferior survival rates of DM patients on insulin
therapy with 33% mortality in these patients compared with 16.6% in
patients on oral therapy [29]. The difference between this study and
the present analysis stems, most likely, from the relatively small
sample size of both cohorts and thus the association between insulin
therapy and TAVR outcome is not yet established.nderwent transcatheter aortic valve replacement at baseline and at 1 year (p N 0.1 for all
Fig. 5. Rates of transition between left ventricular geometric patterns in diabetic and non-diabetic patients at 1 year follow-up post-transcatheter aortic valve replacement (p N 0.1 for all
intergroup comparison).
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HbA1c is an acceptable laboratory index reﬂecting themean serum glu-
cose concentrations in the 2–3 months prior to the procedure and is
now being used in the diagnosis of DM. Several previous studies have
indicated that high pre-operative HbA1c values in diabetics undergoing
coronary artery bypass grafting surgerywere associatedwith prolonged
hospitalization, sternal infection, and poor long-term outcome [35–38].
The fact that TAVR is a less invasive technique compared with surgery
may have led to the lack of outcome differences in patients from differ-
ent strata of glycemic control.
The pressure overload induced on themyocardiumby AS results in LV
hypertrophy. This process is expected to reverse, at least in part, after the
alleviation of aortic valve stenosis. Since DM is also associatedwith LV hy-
pertrophy [39], the interplay between AS and DM after TAVR is especially
interesting. Lindman et al. have reported that DMpatients have higher LV
mass in comparison to other patients with AS [40]. This was also evident
in the present analysis but when this was adjusted to body surface area,
these differenceswere no longer signiﬁcant. This challenges the paradigm
that DM has an additive effect to hypertrophy in AS. Further, when the
degree of mass regression is explored, no differences in mass regression
were noted. Similarly, a lack of disparity of LV mass regression was
demonstrated after TAVR in a sub-analysis of the PARTNER trial, DM
was not associated with greater mass regression [41].
It is plausible that the population of patients referred to TAVR is
inherently different from the general population referred to surgical
aortic valve replacement. TAVR patients are usually older and have
other co-morbidities other than DM and thus the processes governing
both hypertrophy and regression are driven by these comorbidities
collectively with lesser impact of DM on either the LV mass or the
mass regression.
Speciﬁc LV geometry patterns were previously associated with out-
come [42]. In accordance to prior reports [7], the present study demon-
strates that concentric hypertrophy is the most common LV geometry
pattern in both DM and ND patients with concomitant AS; and similarly
to the PARTNER data, the regression of LVmass in the present studywas
mostly directed from concentric hypertrophic towards concentric re-
modeling in both DM and ND patients. Although the prognosis of the
concentric remodeling pattern is better compared to that of concentric
hypertrophy [43], this pattern of concentric remodeling, due to the
lower stroke volume comparedwith normal LV geometry, is still associ-
ated with poor outcome [42].
Although most of the explored outcome metrics were similar
between the two groups, ND patients had higher rates of vascularcomplications and a higher rate in the need for blood transfusion,
which led to prolonged hospitalization. Two explanations may have
led to these results: First, the baseline characteristics were not iden-
tical between the two groups. The ND patients were older with more
females and lower body weights. Female gender and small body size
have previously been associated with higher rates of vascular com-
plications and need for transfusions [44–46]. More importantly,
these differences did not translate into differences in both short-
and long-term mortality. A second explanation for this disparity in
complication rate may have stemmed from the differences in the
sample sizes between groups.
5. Limitations
The present study has several limitations. First, this is a single-
center, non-randomized, retrospective analysis and is thus exposed to
obvious biases. The size of the twomain groups and naturally the num-
ber of patients included in the sub-group analysis may hamper drawing
effective conclusions regarding the effect of glycemic control on out-
come. Second, a surgical comparator groupwas not available; therefore,
the ability to generalize the preference of TAVR over surgical aortic
valve replacement in diabetic patients is limited. Third, a complete
data from the referring physician regarding the time for diagnosis of
DM to TAVR and the exact time on speciﬁc therapeutic strategy was
not available. Lastly, interpretation of the subanalyses should be
cautious due to the relatively small sample size.
6. Conclusion
As opposed to other baseline characteristics and procedural aspects,
diabetes mellitus is not associated with poor outcome after TAVR.
Further, patients with diabetes had similar rates of reverse remodeling
in comparison to non-diabetic patients.
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